Skip to main navigation Skip to search Skip to main content

Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection

  • Devon Foster
  • , Ronnie Sebro
  • , Hillary Garner
  • , Rupert Stanborough
  • , Aaron C. Spaulding
  • , Krista Goulding
  • , Matthew Houdek
  • , Benjamin Wilke

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery. The use of TXA during orthopedic procedures has gained widespread acceptance, with multiple clinical studies demonstrating no increase in thrombotic complications. While TXA has been shown to be safe and effective for several orthopedic procedures, its use in orthopedic sarcoma surgery is not well established. Cancer-associated thrombosis remains a significant cause of morbidity and mortality in patients with sarcoma. It is unknown if intraoperative TXA use will increase the risk of developing a postoperative thrombotic complication in this population. This study aimed to compare the risk of postoperative thrombotic complications in patients who received TXA during sarcoma resection to patients who did not receive TXA. Methods: A retrospective review was performed of 1099 patients who underwent resection of a soft tissue or bone sarcoma at our institution between 2010 and 2021. Baseline demographics and postoperative outcomes were compared between patients who did and did not receive intraoperative TXA. We evaluated 90-day complication rates, including: deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), cerebrovascular accident (CVA), and mortality. Results: TXA was used more commonly for bone tumors (p < 0.001), tumors located in the pelvis (p = 0.004), and larger tumors (p < 0.001). Patients who received intraoperative TXA were associated with a significant increase in developing a postoperative DVT (odds ratio [OR]: 2.22, p = 0.036) and PE (OR: 4.62, p < 0.001), but had no increase in CVA, MI, or mortality (all p > 0.05) within 90 days of surgery, following univariate analysis. Multivariable analysis confirmed that TXA was independently associated with developing a postoperative PE (OR: 10.64, 95% confidence interval: 2.23–50.86, p = 0.003). We found no association with DVT, MI, CVA, or mortality within 90 days postoperatively, following intraoperative TXA use. Conclusion: Our results demonstrate a higher associated risk of PE following TXA use in sarcoma surgery and caution is warranted with TXA use in this patient population.

Original languageEnglish (US)
Pages (from-to)869-876
Number of pages8
JournalJournal of Surgical Oncology
Volume128
Issue number5
DOIs
StatePublished - Oct 2023
Externally publishedYes

Keywords

  • perioperative complications
  • sarcoma
  • tranexamic acid

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection'. Together they form a unique fingerprint.

Cite this